Merck announces top-line results from phase 3 trials evaluating Gefapixant

This article was originally published here

In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically significant decrease in 24-hour coughs per

The post Merck announces top-line results from phase 3 trials evaluating Gefapixant appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply